Responses
Clinical and epidemiological research
Concise report
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase
Compose a Response to This Article
Other responses
No responses have been published for this article.